The Pharma Letter Pharmaletter News Articles
Lilly leads calls for post-Brexit Anglo-American trade deal
The importance of the UK to Eli Lilly as both an operations base and a market has been made evident by…
What does China’s open policy mean to pharma multinationals?
Multinationals (MNCs) were thrilled by China’s recent policies on opening up the domestic pharmaceutical…
Latest major approval for Juluca
ViiV Healthcare and Janssen have received the nod from the European Commission (EC) for the first two-drug…
BRIEF—Accent raises $40 million to develop RNA-modifying technology
Massachusetts, USA-based oncology specialist Accent Therapeutics has raised $40 million in a series A…
BRIEF—Cipla and Stempeutics Research ink licensing deal
Indian pharmaceutical company Cipla and biotech firm Stempeutics Research have agreed a licensing deal…
BRIEF—Breakthrough and fast track designations for pitolisant
USA-based Harmony Biosciences today announced that it has received Breakthrough Therapy and Fast Track…
Strong new comparative data for Refixia in hemophilia B
Adults with hemophilia B who received a single dose Refixia (nonacog beta pegol; N9-GP) achieved greater…
New vaccine company set up by Korean biopharma
GC Pharma, a South Korean biopharma formerly known as Green Cross Corporation, has set up a USA-based…
Pass pharma discounts onto patients, not ‘highly-paid middlemen’, says expert
The part that pharmacy benefit managers (PBMs), insurers and pharmacies play in increasing the prices…
Roche reveals full positive data for Hemlibra in key hemophilia A indication
Switzerland’s Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have released…
Boost for UTILITY in effort to bring new antibiotics to the USA
Newly-formed UTILITY therapeutics, which is focused on developing and commercializing antibiotics, has…
FDA alerts on efficacy issues for some patients taking Keytruda and Tecentriq in urothelial cancer trials
The US Food and Drug Administration is alerting health care professionals, oncology clinical investigators,…
FDA approves Lokelma approved for the treatment of adults with hyperkalemia
Following a complete response letter issued by the agency in March 2017, the US Food and Drug Administration…
BRIEF—Regulatory submission in Japan for Forxiga in type 1 diabetes
AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and…
Study reveals NovoEight retains potency at temperatures as high as 40°c
A long-term study has shown that NovoEight (turoctocog alfa) remains effective after three months of…
Look back at pharma news in week to May 18
US President Donald Trump at last revealed his ‘Blueprint for drug pricing’ which was not as bad…
New Nucala data shows prolonged effect
GlaxoSmithKline has strengthened the data set supporting its anti-IL5 biologic treatment Nucala (mepolizumab)…
At the frontier of brain tumor research, we must leave no stone unturned
In our latest Special Report, Ali Hansford, head of social policy at the Association of the British Pharmaceutical…
BRIEF — Encouraging trial results for Daiichi anti-stroke therapy
Daiichi Sankyo's Lixiana (edoxaban) has announced positive results from the ENGAGE AF-TIMI 48 trial,…
EMA’s PRAC concludes two referrals, and more
At its May 14-17 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…
Danger looms as Agile contests third FDA rejection
Agile Therapeutics has indicated its intention to contest the US Food and Drug Administration's (FDA)…
BRIEF—Another Alzheimer’s drug candidate bites the dust
Pharma major Janssen has announced that it is stopping the screening, randomization and dosing of atabecestat…
BRIEF—HiFiBiO Therapeutics attracts $37.5 million series B investment
HiFiBiO Therapeutics, a biotech startup with offices in China, France and the USA, has won $37.5m in…
Takeda mulls spinning out assets to focus R&D after Shire merger
Talking to investors in London, Takeda Pharmaceutical's chief executive Christophe Weber said his firm…
Landmark approval for new mode of action against migraines
The first ever approval in a new and much-anticipated class of therapy, calcitonin gene-related peptide…
BRIEF—ICER to review biologic treatments for asthma
The USA’s Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining…
Soft first quarter tests patience in AstraZeneca's promise for growth
In its first quarterly results statement of 2018, AstraZeneca says it brought in $5.2 billion sales,…
Public shaming for companies accused of blocking generics
As part of the White House's ongoing mission to reduce the cost of drugs for consumers, US Food and Drug…
BRIEF — Sun Pharma launches Welchol generic in US
Indian generics major Sun Pharmaceuticals has announced its introduction of a generic equivalent to Daiichi…
Early-stage LOXO-292 data sends Loxo shares soaring
Shares of US biotech Loxo Oncology leapt 21% to $167.53 after the firm released an abstract of early-stage…
Feed Fetched by RSS Dog.